Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study

Abstract Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In addition, novel antidepressants such as ketamine have sparse optimization evidence. Insights obtained from metabolomics may improve the management of...

Full description

Bibliographic Details
Main Authors: Jon Berner, Animesh Acharjee
Format: Article
Language:English
Published: Springer 2024-04-01
Series:Discover Mental Health
Online Access:https://doi.org/10.1007/s44192-024-00066-5
_version_ 1797199646426136576
author Jon Berner
Animesh Acharjee
author_facet Jon Berner
Animesh Acharjee
author_sort Jon Berner
collection DOAJ
description Abstract Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In addition, novel antidepressants such as ketamine have sparse optimization evidence. Insights obtained from metabolomics may improve the management of patients. The objective of this study was to determine whether compounds in the cerebrospinal fluid (CSF) metabolome correlate with scores on questionnaires and response to medication. We performed a retrospective pilot study to evaluate phenotypic and metabolomic variability in patients with treatment-resistant depression using multivariate data compression algorithms. Twenty-nine patients with treatment-resistant depression provided fasting CSF samples. Over 300 metabolites were analyzed in these samples with liquid chromatography-mass spectrometry. Chart review provided basic demographic information, clinical status with self-reported questionnaires, and response to medication. Of the 300 metabolites analyzed, 151 were present in all CSF samples and used in the analyses. Hypothesis-free multivariate analysis compressed the resultant data set into two dimensions using Principal Component (PC) analysis, accounting for ~ 32% of the variance. PC1 accounted for 16.9% of the variance and strongly correlated with age in one direction and 5-methyltetrahydrofolate, homocarnosine, and depression and anxiety scores in the opposite direction. PC2 accounted for 15.4% of the variance, with one end strongly correlated with autism scores, male gender, and cognitive fatigue scores, and the other end with bipolar diagnosis, lithium use, and ethylmalonate disturbance. This small pilot study suggests that complex treatment-resistant depression can be mapped onto a 2-dimensional pathophysiological domain. The results may have implications for treatment selection for depression subtypes.
first_indexed 2024-04-24T07:19:04Z
format Article
id doaj.art-f5f5eda0bb57494cbfb86e979c2c793f
institution Directory Open Access Journal
issn 2731-4383
language English
last_indexed 2024-04-24T07:19:04Z
publishDate 2024-04-01
publisher Springer
record_format Article
series Discover Mental Health
spelling doaj.art-f5f5eda0bb57494cbfb86e979c2c793f2024-04-21T11:10:29ZengSpringerDiscover Mental Health2731-43832024-04-014111210.1007/s44192-024-00066-5Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot studyJon Berner0Animesh Acharjee1Woodinville Psychiatric AssociatesInstitute of Cancer and Genomics Sciences, University of BirminghamAbstract Depression is a disorder with variable presentation. Selecting treatments and dose-finding is, therefore, challenging and time-consuming. In addition, novel antidepressants such as ketamine have sparse optimization evidence. Insights obtained from metabolomics may improve the management of patients. The objective of this study was to determine whether compounds in the cerebrospinal fluid (CSF) metabolome correlate with scores on questionnaires and response to medication. We performed a retrospective pilot study to evaluate phenotypic and metabolomic variability in patients with treatment-resistant depression using multivariate data compression algorithms. Twenty-nine patients with treatment-resistant depression provided fasting CSF samples. Over 300 metabolites were analyzed in these samples with liquid chromatography-mass spectrometry. Chart review provided basic demographic information, clinical status with self-reported questionnaires, and response to medication. Of the 300 metabolites analyzed, 151 were present in all CSF samples and used in the analyses. Hypothesis-free multivariate analysis compressed the resultant data set into two dimensions using Principal Component (PC) analysis, accounting for ~ 32% of the variance. PC1 accounted for 16.9% of the variance and strongly correlated with age in one direction and 5-methyltetrahydrofolate, homocarnosine, and depression and anxiety scores in the opposite direction. PC2 accounted for 15.4% of the variance, with one end strongly correlated with autism scores, male gender, and cognitive fatigue scores, and the other end with bipolar diagnosis, lithium use, and ethylmalonate disturbance. This small pilot study suggests that complex treatment-resistant depression can be mapped onto a 2-dimensional pathophysiological domain. The results may have implications for treatment selection for depression subtypes.https://doi.org/10.1007/s44192-024-00066-5
spellingShingle Jon Berner
Animesh Acharjee
Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study
Discover Mental Health
title Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study
title_full Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study
title_fullStr Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study
title_full_unstemmed Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study
title_short Cerebrospinal fluid metabolomes of treatment-resistant depression subtypes and ketamine response: a pilot study
title_sort cerebrospinal fluid metabolomes of treatment resistant depression subtypes and ketamine response a pilot study
url https://doi.org/10.1007/s44192-024-00066-5
work_keys_str_mv AT jonberner cerebrospinalfluidmetabolomesoftreatmentresistantdepressionsubtypesandketamineresponseapilotstudy
AT animeshacharjee cerebrospinalfluidmetabolomesoftreatmentresistantdepressionsubtypesandketamineresponseapilotstudy